Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CD20 × CD3 bispecific T-cell engager

Glofitamab (Specialist drug)

Brand names: Columvi

Glofitamab is a CD20-directed CD3 T-cell engaging bispecific monoclonal antibody used to treat relapsed or refractory diffuse large B-cell lymphoma.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD20 on B cells and CD3 on T cells simultaneously, redirecting T cells to lyse malignant B cells.

Prescribing in practice

  • Cytokine release syndrome is a serious risk, mitigated by step-up dosing and obinutuzumab pretreatment, and patients require close monitoring with prompt management.
  • Treatment is initiated and supervised in centres equipped to manage cytokine release syndrome and neurological toxicity.
  • Neurological adverse effects, serious infections and tumour flare can occur, warranting vigilance and infection prophylaxis where indicated.

Monitoring

Monitor for cytokine release syndrome, neurological symptoms, infection and blood counts, particularly around each step-up dose.

Counselling the patient

  • Report fever, chills, breathlessness, confusion or severe headache immediately.
  • Carry the patient alert information provided and seek urgent care for any new symptoms.
  • Keep up to date with the monitoring schedule, especially during early dosing.

Evidence & guidelines

Efficacy in relapsed or refractory DLBCL was demonstrated in a pivotal phase I/II study reported in the New England Journal of Medicine.

Reference: NICE TA927; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways